Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy DOI Open Access

Sanxiong Huang,

Juling Xu,

Natalia Baran

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 181, P. 117753 - 117753

Published: Dec. 1, 2024

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. However, its effectiveness against solid tumors remains constrained by challenges such as exhaustion, limited persistence, and off-target effects. These highlight critical gaps in current CAR-T cell therapeutic strategies, particularly for tumor applications. Circular RNAs (circRNAs) represent a transformative class non-coding RNAs, known their exceptional stability precise regulatory functions, positioning them promising candidates enhancing next-generation therapies. Notably, circRNAs can bridge gap between preclinical research clinical application offering innovative solutions to overcome technical hurdles improve outcomes. Despite potential, remain underexplored therapies tumors, presenting significant opportunity innovation. The mechanisms through which modulate specificity are not yet fully understood, challenges, achieving efficient targeted circRNA delivery, still need be addressed. This review highlights importance integrating into enhance specificity, minimize effects, durability. By emphasizing potential identifying key gaps, this provides roadmap advancing setting stage next generation personalized cancer treatments.

Language: Английский

Engineering strategies to safely drive CAR T-cells into the future DOI Creative Commons
Matteo Rossi, Eytan Breman

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 19, 2024

Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment the last decade, giving unprecedented results against hematological malignancies. All approved CAR products, as well many being assessed clinical trials, are generated using viral vectors to deploy exogenous genetic material into T-cells. Viral have long-standing history gene delivery, and thus underwent iterations of optimization improve their efficiency safety. Nonetheless, capacity integrate semi-randomly host genome makes them potentially oncogenic via insertional mutagenesis dysregulation key cellular genes. Secondary cancers following administration appear be rare adverse event. However several cases documented few years put spotlight on this issue, which might been underestimated so far, given relatively recent deployment therapies. Furthermore, initial successes obtained malignancies not yet replicated solid tumors. It is now clear that further enhancements needed allow T-cells increase long-term persistence, overcome exhaustion cope with immunosuppressive tumor microenvironment. To aim, variety genomic engineering strategies under evaluation, most relying CRISPR/Cas9 or other editing technologies. These approaches liable introduce unintended, irreversible alterations product cells. In first part review, we will discuss non-viral used for generation T-cells, whereas second focus non-gene engineering, particular regard advantages, limitations, Finally, critically analyze different combinations, delineating superior safety profile production next-generation T-cell.

Language: Английский

Citations

9
The complexity of immune evasion mechanisms throughout the metastatic cascade DOI

Nicole M. Haynes,

Thomas B Chadwick, Belinda S. Parker

et al.

Nature Immunology, Journal Year: 2024, Volume and Issue: 25(10), P. 1793 - 1808

Published: Sept. 16, 2024

Language: Английский

Citations

9
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023 DOI Creative Commons
Qing Huang, Huimin Li,

Yuan Zhang

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: July 3, 2024

Recently, CAR-T cell therapy in hematological malignancies has received extensive attention. The objective of this study is to gain a comprehensive understanding the current research status, development trends, hotspots, and emerging topics pertaining cells treatment malignancies. Articles for from years 2012 2023 were obtained assessed Web Science Core Collection (WoSCC). A bibliometric approach was employed conduct scientific, comprehensive, quantitative analysis, as well visual particular domain. analysis conducted on corpus 3643 articles, which collaboratively authored by 72 countries various institutions. treating shows an increasing trend each year. Notably, identified institutions displaying highest level activity, journals with most citations output, authors who garnered frequency co-citations. Furthermore, successfully hotspots highlighted six within This exploration about 2023. findings will serve valuable reference guide researchers seeking delve deeper into field determine future direction their research.

Language: Английский

Citations

7
Anticancer drugs: where are we now? DOI Creative Commons
Giuseppina De Simone, Claudiu T. Supuran

Expert Opinion on Therapeutic Patents, Journal Year: 2024, Volume and Issue: 34(7), P. 525 - 527

Published: May 9, 2024

Language: Английский

Citations

4
T-cell Redirecting Therapies in Haematological malignancies: Current Developments and Novel Strategies for Improved Targeting DOI Creative Commons
Georgina S.F. Anderson, Michael A. Chapman

Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(9), P. 2856 - 2891

Published: Aug. 5, 2024

T cell-redirecting therapies (TCRTs), such as chimeric antigen receptor (CAR) or cell (TCR) cells and engagers, have emerged a highly effective treatment modality, particularly in the B plasma cell-malignancy setting. However, many patients fail to achieve deep durable responses; while lack of truly unique tumor antigens, concurrent on-target/off-tumor toxicities, hindered development TCRTs for other cancers. In this review, we discuss recent developments TCRT targets hematological malignancies, well novel targeting strategies that aim address these, other, challenges.

Language: Английский

Citations

4
Blood cancer therapy with synthetic receptors and CRISPR technology DOI
Haiying Zhang,

Mingxin Zhong,

Jingdong Zhang

et al.

Leukemia Research, Journal Year: 2025, Volume and Issue: 150, P. 107646 - 107646

Published: Jan. 9, 2025

Language: Английский

Citations

0
Advances in Gene Editing Technologies for Cancer Therapy DOI Creative Commons
Zheng Zhang

Theoretical and Natural Science, Journal Year: 2025, Volume and Issue: 89(1), P. 52 - 56

Published: Jan. 15, 2025

Using gene editing techniques, cancer treatments are being transformed into new ones that precisely alter genetic patterns. The usefulness, difficulties, and future potential of HDR, Base Editing, Prime Editing assessed in this review. While HDR provides accurate repair, its specificity efficiency not as strong. base shows promise correcting flaws, it must be used with caution to reduce unintended consequences. A technique called makes more secure possible without rupturing DNA. Despite their huge potential, advancement areas like security, ethics, efficacy distribution is crucial. article examines these techniques' for treating by compiling research on them.

Language: Английский

Citations

0
Defeating Cancer with Armed Antibodies and Genetically Modified Immune Cells DOI Creative Commons
Liang Zhao

Highlights in Science Engineering and Technology, Journal Year: 2025, Volume and Issue: 129, P. 57 - 66

Published: March 3, 2025

Cancer has been one of the primary causes lethality worldwide, driving demand for innovative treatments alongside traditional methods like surgery, chemotherapy and radiotherapy. Advances in immunotherapy, particularly with antibody-drug conjugators (ADCs) genetically modified immune cells, such as CAR-T TCR-T are bringing goal defeating cancer closer to reality. ADCs enable precise delivery cytotoxic drugs cells while sparing healthy tissue; engineered enhance targeting against tumours. However, these therapies still need overcome challenges, including side effects, production complexity, high costs. A synergistic approach that combines can solve problem tumour heterogeneity drug resistance. This dual-targeting strategy amplifies cell by combining ADC-induced cytotoxicity a sustained response from cells. In addition, early clinical trials have demonstrated this combination therapy, especially drug-resistant cancers, improves patient survival reduces recurrence rates. Although synergetic therapy is facing problems regarding immune-related effects accessibility, integration effectively enhances which personalised, long-lasting, effective.

Language: Английский

Citations

0
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies DOI Creative Commons
Yunlong Liu, Changjun Wang, Xiuping Fu

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 376 - 376

Published: March 5, 2025

Nucleic-acid-based therapies have emerged as a pivotal domain within contemporary biomedical science, marked by significant advancements in recent years. These innovative treatments primarily operate through the precise binding of DNA or RNA molecules to discrete target genes, subsequently suppressing expression proteins. The spectrum nucleic-acid-based encompasses antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), and messenger (mRNAs), etc. Compared more traditional medicinal approaches, stand out for their highly targeted action on specific well potential chemical modification improve resistance nucleases, ensuring sustained therapeutic activity mitigating immunogenicity concerns. Nevertheless, these molecules’ limited cellular permeability necessitates deployment delivery vectors enhance intracellular uptake stability. As progressively display promising pharmacodynamic profiles, there has been burgeoning interest applications clinical research. This review aims summarize variety nucleic acid drugs mechanisms, evaluate present status research application, discourse prospective trends, challenges ahead. therapeutics are anticipated assume role management wide array diseases.

Language: Английский

Citations

0
Revolutionizing healthcare: the role of CRISPR-Cas systems in precision medicine DOI Creative Commons
Kirolos Eskandar

Pharmacogenetics and Pharmacogenomics, Journal Year: 2025, Volume and Issue: 2, P. 29 - 36

Published: March 4, 2025

Introduction. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has been recognized as a revolutionary advancement in the biomedical field, offering unparalleled precision and versatility genome editing. This review examines transformative potential of diagnostic therapeutic tool for various diseases. Methods. A systematic was conducted following PRISMA (Preferred Reporting Items Systematic Reviews Meta-Analyses) guidelines. comprehensive search PubMed, Scopus, Google Scholar, Web Science performed to identify relevant Studies published between January 2015 2025. The inclusion criteria focused on peer-reviewed articles discussing CRISPR-based diagnostics, applications, technological advancements. were screened, assessed quality using CASP framework, categorized into thematic areas analysis. Results. platforms, such SHERLOCK DETECTR, analyzed their sensitivity rapidity detecting pathogens, cancer biomarkers, genetic mutations. Emerging innovations, including prime base editing, have explored role expanding capabilities CRISPR. Additionally, advancements delivery mechanisms use alternative Cas proteins discussed impact clinical applicability. Conclusions. Ethical, regulatory, accessibility challenges associated with technology are highlighted, emphasizing importance responsible development equitable deployment. connects cutting-edge translational underscores significant shaping future medicine global health.

Language: Английский

Citations

0